| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/04/2024 | 15:00 | GlobeNewswire Inc. | XOMA Corporation Announces Closing of Tender Offer | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 19/03/2024 | 21:05 | GlobeNewswire Inc. | XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 05/03/2024 | 23:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 04/03/2024 | 23:27 | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 01/03/2024 | 14:53 | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 01/03/2024 | 14:50 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 01/03/2024 | 14:35 | PR Newswire (US) | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 01/03/2024 | 14:30 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 16/02/2024 | 23:57 | PR Newswire (US) | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc. | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 16/02/2024 | 16:46 | PR Newswire (US) | Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law Firm | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 16/02/2024 | 14:00 | GlobeNewswire Inc. | XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 16/02/2024 | 14:00 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 14/02/2024 | 15:21 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 09/11/2023 | 22:21 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 09/11/2023 | 22:05 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 18/09/2023 | 22:10 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 08/08/2023 | 22:05 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 14/06/2023 | 00:33 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 12/06/2023 | 22:06 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 01/06/2023 | 22:05 | GlobeNewswire Inc. | Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 11/05/2023 | 22:27 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 11/05/2023 | 22:05 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 08/05/2023 | 23:02 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 28/04/2023 | 22:18 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 28/04/2023 | 22:18 | Edgar (US Regulatory) | Annual Report to Security Holders (ars) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 17/04/2023 | 20:35 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 17/04/2023 | 20:30 | GlobeNewswire Inc. | First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 06/04/2023 | 15:30 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 17/03/2023 | 21:23 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:KNTE | Kinnate Biopharma Inc |
| 15/03/2023 | 21:05 | GlobeNewswire Inc. | Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates | NASDAQ:KNTE | Kinnate Biopharma Inc |